in

syngene international: Syngene’s capex on track; focus on R&D and biologics to fuel future expansion: Jonathan Hunt

“We were successful during the course of converting a number of those into permanent contracts and that will give us a foundation for growth as we go into the future,” says Jonathan Hunt, Syngene International.

It was a good quarter coming in when you talk about the third quarter. But I also…

Read More

What do you think?

Written by pulseadmin

Leave a Reply

Your email address will not be published. Required fields are marked *

GIPHY App Key not set. Please check settings

RIL, Zomato, Trent among 10 largecap stocks where FIIs cut stakes in Q3 FY25 – Fall From Favour

MFs continue reducing holdings in 8 stocks, prices fall 25-60% in FY25 – Portfolio Watch